STARD5 and metabolic dysfunction-associated steatohepatitis: However, continued suppression of StarD5 with a continuing supply of lipid excess promotes continued lipid storage, development of IR, likely toxic levels of cholesterol metabolite accumulation, and accelerated fibrosis, all hallmarks of lipid-related disease of the liver (MASLD/MASH).